6 research outputs found
Evaluating Alkaline Phosphatase-Instructed Self-Assembly of d‑Peptides for Selectively Inhibiting Ovarian Cancer Cells
Cancer is a major public health concern requiring novel
treatment
approaches. Enzyme-instructed self-assembly (EISA) provides a unique
approach for selectively inhibiting cancer cells. However, the structure
and activity correlation of EISA remains to be explored. This study
investigates new EISA substrates of alkaline phosphatase (ALP) to
hinder ovarian cancer cells. Analogues 2–8 were
synthesized by modifying the amino acid residues of a potent EISA
substrate 1 that effectively inhibits the growth of OVSAHO,
a high-grade serous ovarian cancer (HGSOC) cell line. The efficacy
of 2–8 against OVSAHO was assessed, along with
the combination of substrate 1 with clinically used drugs.
The results reveal that substrate 1 displays the highest
cytotoxicity against OVSAHO cells, with an IC50 of around
8 μM. However, there was limited synergism observed between
substrate 1 and the tested clinically used drugs. These
findings indicate that EISA likely operates through a distinct mechanism
that necessitates further elucidation
Evaluating Alkaline Phosphatase-Instructed Self-Assembly of d‑Peptides for Selectively Inhibiting Ovarian Cancer Cells
Cancer is a major public health concern requiring novel
treatment
approaches. Enzyme-instructed self-assembly (EISA) provides a unique
approach for selectively inhibiting cancer cells. However, the structure
and activity correlation of EISA remains to be explored. This study
investigates new EISA substrates of alkaline phosphatase (ALP) to
hinder ovarian cancer cells. Analogues 2–8 were
synthesized by modifying the amino acid residues of a potent EISA
substrate 1 that effectively inhibits the growth of OVSAHO,
a high-grade serous ovarian cancer (HGSOC) cell line. The efficacy
of 2–8 against OVSAHO was assessed, along with
the combination of substrate 1 with clinically used drugs.
The results reveal that substrate 1 displays the highest
cytotoxicity against OVSAHO cells, with an IC50 of around
8 μM. However, there was limited synergism observed between
substrate 1 and the tested clinically used drugs. These
findings indicate that EISA likely operates through a distinct mechanism
that necessitates further elucidation
Algorithm for Designing Nanoscale Supramolecular Therapeutics with Increased Anticancer Efficacy
In
the chemical world, evolution is mirrored in the origin of nanoscale
supramolecular structures from molecular subunits. The complexity
of function acquired in a supramolecular system over a molecular subunit
can be harnessed in the treatment of cancer. However, the design of
supramolecular nanostructures is hindered by a limited atomistic level
understanding of interactions between building blocks. Here, we report
the development of a computational algorithm, which we term Volvox
after the first multicellular organism, that sequentially integrates
quantum mechanical energy-state- and force-field-based models with
large-scale all-atomistic explicit water molecular dynamics simulations
to design stable nanoscale lipidic supramolecular structures. In one
example, we demonstrate that Volvox enables the design of a nanoscale
taxane supramolecular therapeutic. In another example, we demonstrate
that Volvox can be extended to optimizing the ratio of excipients
to form a stable nanoscale supramolecular therapeutic. The nanoscale
taxane supramolecular therapeutic exerts greater antitumor efficacy
than a clinically used taxane <i>in vivo</i>. Volvox can
emerge as a powerful tool in the design of nanoscale supramolecular
therapeutics for effective treatment of cancer
Algorithm for Designing Nanoscale Supramolecular Therapeutics with Increased Anticancer Efficacy
In
the chemical world, evolution is mirrored in the origin of nanoscale
supramolecular structures from molecular subunits. The complexity
of function acquired in a supramolecular system over a molecular subunit
can be harnessed in the treatment of cancer. However, the design of
supramolecular nanostructures is hindered by a limited atomistic level
understanding of interactions between building blocks. Here, we report
the development of a computational algorithm, which we term Volvox
after the first multicellular organism, that sequentially integrates
quantum mechanical energy-state- and force-field-based models with
large-scale all-atomistic explicit water molecular dynamics simulations
to design stable nanoscale lipidic supramolecular structures. In one
example, we demonstrate that Volvox enables the design of a nanoscale
taxane supramolecular therapeutic. In another example, we demonstrate
that Volvox can be extended to optimizing the ratio of excipients
to form a stable nanoscale supramolecular therapeutic. The nanoscale
taxane supramolecular therapeutic exerts greater antitumor efficacy
than a clinically used taxane <i>in vivo</i>. Volvox can
emerge as a powerful tool in the design of nanoscale supramolecular
therapeutics for effective treatment of cancer
Characterization of distinct peptides identified from mouse plasma reference sets
The histogram of peptide length of unique sequences in mouse PeptideAtlas (blue) is overlaid on an tryptic digest of the IPI mouse database (black).<p><b>Copyright information:</b></p><p>Taken from "A mouse plasma peptide atlas as a resource for disease proteomics"</p><p>http://genomebiology.com/2008/9/6/R93</p><p>Genome Biology 2008;9(6):R93-R93.</p><p>Published online 3 Jun 2008</p><p>PMCID:PMC2481425.</p><p></p
Genomic mapping of mouse peptide LLEAQIATGGIIDPK using UCSC Blast program
Mouse splice variant M13C2563_1_s386_e8960_1_rf2_c1_n0 was identified with 13 distinct peptides. Twelve peptides matched a predicted mouse protein similar to desmoplakin using a homolog search against the NCBI NR database. However, all 13 peptides were homologous to the human desmoplakin sequence. Of note, mouse peptide LLEAQIATGGIIDPK aligns to the coding sequence of human desmoplakin, but not to the annotated mouse desmoplakin gene.<p><b>Copyright information:</b></p><p>Taken from "A mouse plasma peptide atlas as a resource for disease proteomics"</p><p>http://genomebiology.com/2008/9/6/R93</p><p>Genome Biology 2008;9(6):R93-R93.</p><p>Published online 3 Jun 2008</p><p>PMCID:PMC2481425.</p><p></p